Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 1, 2011.
Article Versions
- You are currently viewing a Latest version of this article (February 1, 2011 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2011 The Journal of Rheumatology
Author Information
- Edward C. Keystone,
- Arthur Kavanaugh,
- Michael E. Weinblatt,
- Kaushik Patra and
- Aileen L. Pangan
- From the Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; University of California–San Diego, San Diego, California, USA; Brigham and Women’s Hospital, Boston, Massachusetts, USA; and Abbott Laboratories, Abbott Park, Illinois, USA.
Funded by Abbott Laboratories, Abbott Park, IL, USA. Drs. Keystone and Kavanaugh are study investigators for the DE019 trial. Drs. Keystone, Kavanaugh, and Weinblatt have served as Abbott consultants, and have received research grants from Abbott. Drs. Pangan and Patra are employees of Abbott Laboratories, the manufacturer of adalimumab. E.C. Keystone, MD, Rebecca MacDonald Centre, Mount Sinai Hospital, University of Toronto; A. Kavanaugh, MD, University of California–San Diego; M.E. Weinblatt, MD, Brigham and Women’s Hospital; K. Patra, PhD; A.L. Pangan, MD, Abbott Laboratories.
Address correspondence to Dr. E.C. Keystone, Division of Advanced Therapeutics, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Joseph and Wolf Lebovic Building, 2nd Floor, 60 Murray Street, Toronto, Ontario M5G 1X5. E-mail: edkeystone@mtsinai.on.ca
Full Release Article. For details see Reprints/Permissions at jrheum.org
Accepted for publication December 3, 2010.